Active Ingredient: Ozenoxacin
Ozenoxacin is indicated for the short term treatment of non-bullous impetigo in adults, adolescents, children, and infants aged 6 months and older).
For this indication, competent medicine agencies globally authorize below treatments:
For:
Cutaneous, 1 spreads ozenoxacin, 2 times daily, over the duration of 5 days.
A thin layer of cream should be applied to the affected area twice daily for five days. The treated area may be covered by a sterile bandage or gauze dressing, if desired.
Patients not showing a clinical response within three days should be re-evaluated and alternative therapy should be considered.
The safety and efficacy of ozenoxacin 10 mg/g cream in children under 6 months of age have not been established.
Ozenoxacin cream must be kept away from the eyes and mucous membranes.
Care must be taken to avoid ingestion which is especially important in children who has lesions around the mouth.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
